AstraZeneca COVID shot production is expected to resume in India
Ricardo Ceppi/Getty Images News

Serum Institute of India, the worldâs largest manufacturer of vaccines, could resume production of Covishield, a version of the COVID-19 vaccine developed by AstraZeneca (NASDAQ:AZN) and Oxford University.
Serum Institute already has a stockpile of 6M doses of Covovax, a version of the protein-based COVID vaccine developed by Novavax (NASDAQ:NVAX), Reuters reported Wednesday, citing a company spokesperson.

The announcement coincides with an uptick in COVID cases in India. Early this month, the country requested states to target emergency hotspots and increase COVID-19 testing as case counts jumped ~7.9K on Wednesday, the highest in more than seven months.
Novavax (NVAX) COVID-19 vaccine, identified as NVX-CoV2373, is authorized for use in India in those aged 12 years and above.
Read: Seeking Alpha author Out of Ignorance reaffirmed a Neutral view on NVAX today, citing âsignificant financial uncertaintiesâ as demand for its long commercial product drops amid waning impact of the pandemic.